About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 319 record(s)
Nothing to report this month
Organization: Patented Medicine Prices Review Board Canada
Req # A-2020-00031
Total amount of expenses incurred detailing all expenses with the 2020/2021 object codes 1231, 1246, and 0533 between March 1st 2020 to September 16th, 2020.Organization: Office of the Superintendent of Financial Institutions Canada
October 2020
Nothing to report this month
Organization: Patented Medicine Prices Review Board Canada
Req # A-2020-00030
All modelling, research, presentations, studies, reports, memos, or other material examining longetivity and mortality rates for Black and racialized Canadians from January 1st 2010 to August 2020.Organization: Office of the Superintendent of Financial Institutions Canada
September 2020
Req # A-2020-00040
All OSFI records, documents and correspondence between OSFI and the Financial Consumer Agency of Canada (FCAC), between May 24, 2017 and December 31, 2018 related to "sales practices" at banks and/or a review of "business practices". Also please include the related correspondence with the Department of Finance (in addition to OSFI and FCAC) between May 24, 2017 and December 31, 2018;Organization: Office of the Superintendent of Financial Institutions Canada
September 2020
Req # A-2020-00041
Briefing notes, reports, correspondence and presentations provided BY and TO the superintendent and assistant superintendents regarding OSFI's review of the governance of domestic retail sales practices across the six domestic systemically important banks (D-SIBs) and the related institutional risk culture. Please limit the scope of this request to the period of May 7, 2017 to the present date [May 6, 2019];Organization: Office of the Superintendent of Financial Institutions Canada
September 2020
Req # A-2020-00004
List of mandatory or voluntary training, info sessions, awareness sessions, and sensitivity training from January 1, 2020 to September 2020.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-04135
Copies of the Human Drug Advisory (HDAP) report for erenumab (Aimovig) from January 2018 to February 2020.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-09098
Copies of all records discussing the impacts of the regulatory changes to the PMPRB from August 2019 until August 2020. Copies of all correspondence from all pharmaceutical companies expressing their concerns with the changes and any responses back to these companies. Copies of all correspondence from all advocating groups expressing concerns with the changes and any responses back to these groups. Copies of all correspondence between departmental staff discussing the impacts of the regulatory changes to the PMPRB. Copies of all records discussing the impacts of the PMPRB changes on individuals living with rare diseases. Copies of all correspondence from Vertex Pharmaceuticals relating to Kalydeco, Orkambi, Symdeko, and Trikafta. Copies of all correspondence between government officials (Prime Minister, Ministers, all members of parliament, constituency staff, deputies, assistant deputies, directors, managers, supervisors, staff, and any other employee of the Government of Canada relating to the PMPRB regulatory changes. Copies of all presentations relating to the PMPRB regulatory changes.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-01436
Copies of reports, discussions, briefings, memos and decisions related to the introductory price review for erenumab (Aimovig) from January 2018 to February 2020.Organization: Patented Medicine Prices Review Board Canada
August 2020